Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Cash from Financing Activities: 2020-2024

Historic Cash from Financing Activities for Journey Medical (DERM) over the last 5 years, with Dec 2024 value amounting to $17.0 million.

  • Journey Medical's Cash from Financing Activities rose 2493.88% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year decrease of 16.28%. This contributed to the annual value of $17.0 million for FY2024, which is 453.73% up from last year.
  • As of FY2024, Journey Medical's Cash from Financing Activities stood at $17.0 million, which was up 453.73% from -$4.8 million recorded in FY2023.
  • Over the past 5 years, Journey Medical's Cash from Financing Activities peaked at $53.0 million during FY2021, and registered a low of -$4.8 million during FY2023.
  • Its 3-year average for Cash from Financing Activities is $9.5 million, with a median of $16.5 million in 2022.
  • Per our database at Business Quant, Journey Medical's Cash from Financing Activities skyrocketed by 10,986.24% in 2021 and then slumped by 129.19% in 2023.
  • Journey Medical's Cash from Financing Activities (Yearly) stood at -$487,000 in 2020, then surged by 10,986.24% to $53.0 million in 2021, then plummeted by 68.96% to $16.5 million in 2022, then tumbled by 129.19% to -$4.8 million in 2023, then skyrocketed by 453.73% to $17.0 million in 2024.